Harvard Bioscience opened higher at $9.83, compared with its previous close of $9.68. In the last trading session, the stock traded between $9.21 and $9.97. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Harvard Bioscience is now worth
$ 11.95
Resulting in a loss of
$ 88.05 (88.05%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.43 (-4.44%)
Day High
$9.97
Day Low
$9.21
Day Open
$9.83
Prev Close
$9.68
Volume
14,630
1W Return
7.00%
1M Return
9.92%
3M Return
51.02%
6M Return
35.23%
1Y Return
52.26%
Fundamentals
Market Cap ($ Mn)
42
PE Ratio
-
PB Ratio
4.91
PEG Ratio
-
ROE
-232.93%
ROCE
-129.56%
EPS (TTM)
$-0.64
Investment Returns
1 Week
7.00%
1 Month
9.92%
3 Months
51.02%
6 Months
35.23%
9 Months
70.10%
Financials
Quarterly
All values in $ Mn
21.8
Mar 25
20.4
Jun 25
20.6
Sep 25
23.7
Dec 25
20.8
Mar 26
22.7
Jun 26
Updates
11Nov
StoneX downgrades Harvard Bioscience from Speculative Buy to Hold
StoneX analyst Bruce D. Jackson downgraded Harvard Bioscience. Rating changed from Speculative Buy to Hold. Action reflects updated investment outlook.
Yesterday
10Nov
Harvard Bioscience Q3 revenue up 8% to $22.2M; EBITDA guidance cut
Q3FY26 revenue rose 8% YoY to $22.2 million, driven by organoids and fluidics. Full-year adjusted EBITDA guidance lowered to -1% to 4% from 6% to 10%. China revenue grew 31% YoY, while Europe revenue declined 5% YoY. Project Viking on track for Q1 2027 completion, targeting $4 million annual savings.
2 days ago
7Oct
Harvard Bioscience forms Scientific Advisory Board to guide R&D strategy
Harvard Bioscience established a five-member Scientific Advisory Board to guide R&D and product roadmaps. The board includes CEO John Duke and four industry leaders from STEMCELL Technologies, Harvard Medical School, Ananda Devices, and LabConnect. The SAB will meet quarterly to leverage expertise in drug discovery, translational medicine, and new product launches.
1mo ago
28Jul
Harvard Bioscience Q2 Results: Earnings Call Set for August 11
Harvard Bioscience Inc will report Q2 2026 results on August 11, 2026, with a conference call at 8:00 AM ET. Financial materials will be available on its investor website post-announcement.
